The division—formerly called Scimed—has already added hundreds of jobs in Maple Grove since last summer, most of them related to its new Taxus drug-coated stent, which was developed in Maple Grove. The new stent is expected to get regulatory approval to be sold in the US in a matter of days or weeks. Securities analysts think Boston Scientific will capture a major share of a market that could reach $5 billion in annual sales in the next year or two.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
